Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites - Wikidata - wikimedia - TriplyDB

Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites

Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites

http://www.wikidata.org/entity/Q39753695

about

The 26S proteasome is a multifaceted target for anti-cancer therapies Hydroxyureas as noncovalent proteasome inhibitors Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine Assessing subunit dependency of the Plasmodium proteasome using small molecule inhibitors and active site probes Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones.Nature of pharmacophore influences active site specificity of proteasome inhibitors.Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Identification of a molecular target of a novel fungal metabolite, pyrrolizilactone, by phenotypic profiling systems.Inhibition of human and yeast 20S proteasome by analogues of trypsin inhibitor SFTI-1 Multicolor monitoring of the proteasome's catalytic signature.Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines.Subunit specific inhibitors of proteasomes and their potential for immunomodulation The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.Structure- and function-based design of Plasmodium-selective proteasome inhibitors HSF-1 activates the ubiquitin proteasome system to promote non-apoptotic developmental cell death in C. elegans.Activity-based imaging probes of the proteasome.The proteasome activator PA200 regulates tumor cell responsiveness to glutamine and resistance to ionizing radiation.Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.Proteasome inhibitors: an expanding army attacking a unique target.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Synthesis and pharmacology of proteasome inhibitors.The proteasome of malaria parasites: A multi-stage drug target for chemotherapeutic intervention?Peptide-based proteasome inhibitors in anticancer drug design.Pharmacophore modeling technique applied for the discovery of proteasome inhibitors.Suppression of the Oncogenic Transcription Factor FOXM1 by Proteasome Inhibitors.The future of proteasome inhibitors in relapsed/refractory multiple myeloma.Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.Activity-based probes for the multicatalytic proteasome.Targeting proteasomes in infectious organisms to combat disease.A humanized yeast proteasome identifies unique binding modes of inhibitors for the immunosubunit β5i.Triple bioorthogonal ligation strategy for simultaneous labeling of multiple enzymatic activities.

P2860

Q26795764-3EDE1BE7-09BC-4134-B602-0762FCCA333C Q27675743-465563FF-3A8E-43BC-B34F-496DDB79D7C9 Q27675903-D49B5CEA-ACBF-404F-A115-56EF2970A4F8 Q27702605-32143CCE-87C5-43F7-A6DB-2357109E629E Q34061291-1D473174-BBC5-4D92-BD49-EB25E9E61A4E Q34079904-82E9D2D3-A61F-454D-8DEF-456D25D28ACC Q34401062-E42FF967-1B92-4980-AD1D-4E3996612365 Q34473136-05B3CF32-78FD-4E09-B1A6-A48BEC58ED32 Q34575522-FABB2D9B-21BF-4817-B708-B9131C0CA3A0 Q34608271-66F5377E-C602-42F4-8FA9-5D28457D63D5 Q35027521-4EFF52D1-3A8D-45A4-9A81-39AFE6238D6B Q35107386-053D188B-3BE7-43CB-8245-AAFD765D34FC Q35121111-93646D8E-53BD-4510-B6D8-240103552A2F Q35764713-8CB7788C-6D08-4AE2-B8F4-D9F0341C5015 Q35889653-69EC9C0D-D0B3-4A18-90D3-4F1D2C34348E Q35911674-780669C7-0B50-4B5F-B4A7-B1238FE00A37 Q35969785-FFB34157-286E-4362-9526-9E004E29CD25 Q36037323-EFE33800-3FF4-4F55-A71B-D2E695FF935A Q36042649-07013FB3-7C46-4C41-847D-E854638F7855 Q36115692-52C4683E-7D13-46D2-9C2B-7CEA4E3E9923 Q36290627-64D2AF62-6D56-4573-9556-389DFACA436A Q36354644-03AECB01-BDD7-4D99-8188-A2F3054D0060 Q36584903-5FB82F0E-020D-4EB8-8200-18C1E8A71EBA Q36768058-1FD50FC3-CD59-4875-AA39-9F7A6E373968 Q37136304-4790B088-3713-4E45-AD7A-B373A1467ED8 Q37603650-93C87CCD-A787-46B5-A236-649D49D48048 Q37705854-0ADD7A03-4827-49E9-8040-C546C5819FC2 Q37979388-CD7F6C0C-202A-4DB1-8BFA-6B051B9B8F92 Q38019864-BCEFBD20-BC2E-4F70-9D4E-A30E9FB135C5 Q38092777-08CA4D2A-2966-47A3-90AA-6871CFB17D62 Q38188569-DC3E2CD5-F188-4CD5-A5F4-BD23F5AD4446 Q38192572-C9A72374-9624-4CDE-BC2C-4A2584991DFB Q38216045-7329A0ED-1E40-4DD4-8274-BCD2469A5A28 Q38237068-A56396AA-2DD3-4186-8131-16345E1049E1 Q38246060-5EE4DAE5-5BA7-4076-AA95-B1613806701E Q39034873-60B54C22-C86F-47D7-BC18-2728C7D749A7 Q39096761-BCFA3DC0-DE16-45C5-A318-DF09E630039C Q39103077-4A3B0358-C4F9-45FF-B952-39560ED72EA1 Q39241756-FE985601-94EA-4362-9923-631CAAFBC092 Q39375722-D55C8F59-FB2B-4594-B701-8E5CD0F4D01A

P2860

Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites

http://www.wikidata.org/entity/Q39753695

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Selective inhibitor of proteas ...... ion of chymotrypsin-like sites

@en

Selective inhibitor of proteas ...... on of chymotrypsin-like sites.

@nl

type

label

Selective inhibitor of proteas ...... ion of chymotrypsin-like sites

@en

Selective inhibitor of proteas ...... on of chymotrypsin-like sites.

@nl

prefLabel

Selective inhibitor of proteas ...... ion of chymotrypsin-like sites

@en

Selective inhibitor of proteas ...... on of chymotrypsin-like sites.

@nl

P1433

Q39753695-F469277A-0BFD-4784-9674-7A5686CF01B9

P1476

Q39753695-1144EFF5-15EC-44C4-B3CF-C7ED6EC28B66

P2093

Q39753695-1792B346-D917-4968-9CAA-03636C857F31

Q39753695-3323E11E-A575-4F76-B50F-E4A16AE9F94B

Q39753695-44607AE3-07F8-40CC-82D3-DE7FFAFA1443

Q39753695-5E4A4B28-AFC7-4357-A783-38C6A06D01FB

Q39753695-748BF13B-2A8A-4CA0-B7B6-40DB3904A8CE

Q39753695-83909758-5D9A-43B3-BE03-D68AACC683BC

Q39753695-A730ACB4-479D-49DD-B105-E27314435021

Q39753695-C941CE22-E141-46A4-94D4-9A0304A9414F

Q39753695-F4D19463-008F-4A65-AFA3-36AD84333B04

P2860

Q39753695-02CC46B7-49D2-48E5-8C5D-B95CC6466E57

Q39753695-06251A81-905D-4EFD-BE7B-1496EA13D40C

Q39753695-259DE7B1-F4D2-45FA-8ACF-24DB66CB972C

Q39753695-313BCBBF-A749-4464-AD41-0AB05844B8E5

Q39753695-350554C1-E693-464A-A060-B337974F1C9D

Q39753695-3CF39E6D-9057-4302-948E-513870D78FE7

Q39753695-442DB70A-6CA8-4140-BA03-4A5752FBF072

Q39753695-49001DD7-E8B9-4EC7-9383-9DBEF88A2914

Q39753695-4F284EE5-8CDF-46AF-84FF-E6118A933F15

Q39753695-51737565-AA5A-422E-8C71-EE1DE1497F23

P304

Q39753695-1CDFBA9C-1914-4241-B381-3CF5D7416F47

P31

Q39753695-05D36500-B7C5-4B05-8DBB-DC62120BB39E

P356

Q39753695-C82577C0-0ADD-4A32-A415-B3AB1C4043B5

P433

Q39753695-0C21AEA7-10DF-4BC7-824C-9DEA109D8AB9

P478

Q39753695-52EDF510-B0EE-4EE7-8B1C-4734A004BE1E

P50

Q39753695-1140897A-AC77-45A3-B225-0D69C05895F0

Q39753695-A07AD303-9070-4E46-A2AE-F388C24C2ADF

Q39753695-A1A446B4-9871-4E29-B325-93451045E05B

Q39753695-A4A799C0-9BBF-45F0-BE4E-711C684FECCF

P577

Q39753695-88E44889-47FC-4176-8C16-2B1233BA640C

P5875

Q39753695-F754FDEA-22EC-4328-B4AC-951AA56947CD

P698

Q39753695-BA4DFDEE-505D-4BA5-976E-A98EA0D95DEE

P932

Q39753695-3FEF2333-6DE8-4A5B-B9BD-C5E555CF8C0E

P356

J.CHEMBIOL.2009.11.015

P1433

Chemistry and Biology

P1476

Selective inhibitor of proteas ...... ion of chymotrypsin-like sites

@en

P2093

Alexandre A Pletnev

http://www.w3.org/2001/XMLSchema#string

Alexei F Kisselev

http://www.w3.org/2001/XMLSchema#string

Ayrton L Goddard

http://www.w3.org/2001/XMLSchema#string

Marcella M Lucas

http://www.w3.org/2001/XMLSchema#string

Matthew Britton

http://www.w3.org/2001/XMLSchema#string

Michael Screen

http://www.w3.org/2001/XMLSchema#string

Omar Amir

http://www.w3.org/2001/XMLSchema#string

Philip M Pelphrey

http://www.w3.org/2001/XMLSchema#string

Robert A Tokhunts

http://www.w3.org/2001/XMLSchema#string

P2860

26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide.

Structure of 20S proteasome from yeast at 2.4 A resolution

Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly.

Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation.

The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing.

The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study

The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

P304

1278-1289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CHEMBIOL.2009.11.015

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Herman S Overkleeft

Martijn Verdoes

Dennis L Wright

Sondra L Downey

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40907036

http://www.w3.org/2001/XMLSchema#string

P698

20064438

http://www.w3.org/2001/XMLSchema#string

P932

2807417

http://www.w3.org/2001/XMLSchema#string